Actinogen Medical (ASX:ACW) is an ASX-listed, biotechnology company developing an innovative treatment for cognitive impairment associated with neurological, psychiatric, and metabolic diseases due to raised cortisol. ‘Cognition’ relates to how a person understands and acts in the world around them. Cognitive functions include memory, reasoning, awareness and decision-making, and to a large extent, influences our personality.
Actinogen Medical’s lead drug candidate, Xanamem, has been specifically designed to block the production of cortisol – the stress hormone – in the brain. Chronically elevated cortisol is associated with cognitive decline in Alzheimer’s disease, anxiety in Fragile X syndrome, and cognitive impairment in schizophrenia and diabetes.
Xanamem offers a promising new approach to treat cognitive impairment associated with these neurodegenerative, psychiatric, and metabolic diseases.
In the Company’s recent XanaHES Phase I trial, Xanamem exhibited a statistically significant improvement in cognition among healthy elderly volunteers treated with 20mg Xanamem daily, building on the encouraging data from the earlier XanADu study. The Company plans to initiate a range of Phase II studies evaluating Xanamem in the treatment of cognitive impairment associated with Alzheimer’s disease, Fragile X syndrome, schizophrenia, and diabetes.